Prihlásiť sa Zaregistrujte sa zadarmo

Hotovosť na akciu spoločnosti Inhibrx

Aká je hodnota metriky Hotovosť na akciu spoločnosti Inhibrx?

Hodnota metriky Hotovosť na akciu spoločnosti Inhibrx, Inc. je 3.25

Aká je definícia metriky Hotovosť na akciu?

Hotovosť na akciu (Cash per share) je pomer ihneď dostupných peňazí prístupných na výdaj a vydaných akcií spoločnosti.

Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.

When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.

Hotovosť na akciu spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Inhibrx

Čomu sa venuje spoločnosť Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Firmy s metrikou hotovosť na akciu podobnou spoločnosti Inhibrx